PMID- 38094535
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231214
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 11
DP  - 2023 Nov
TI  - The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the 
      Management of Iron Deficiency in China: A Rapid Health Technology Assessment.
PG  - e48717
LID - 10.7759/cureus.48717 [doi]
LID - e48717
AB  - Intravenous (IV) iron supplementation is the preferred treatment option for 
      managing severe iron deficiency (ID) and ID anemia (IDA). Three of the available 
      IV iron preparations are ferric derisomaltose (FDI), ferric carboxymaltose (FCM), 
      and iron sucrose (IS). The objective of the present work was to review the 
      published literature about the efficacy, safety, quality of life (QoL), and 
      economic outcomes of using FDI, FCM, and IS for the treatment of ID. A systematic 
      literature search was performed following Preferred Reporting Items for 
      Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible studies were 
      assessed for quality using appropriate tools, and data were extracted and 
      analyzed for key outcomes. The evidence synthesis was based on published 
      systematic literature reviews (SLRs), meta-analyses (MAs), indirect treatment 
      comparisons (ITCs), and health technology assessments (HTAs); we also included 
      economic evaluations performed from a Chinese perspective. Out of 337 initial 
      hits, the review included 12 studies. The findings indicated that FDI, FCM, and 
      IS had comparable efficacy in terms of hemoglobin (Hb) improvement. FDI showed a 
      better safety profile with a lower risk of hypophosphatemia, hypersensitivity 
      reactions, and cardiovascular adverse events (AEs) compared to IS and FCM. FDI 
      also demonstrated better cost-effectiveness compared to IS, with potential cost 
      savings attributed to fewer infusions and improved compliance. None of the 
      included studies evaluated QoL after IV iron administration for ID. FDI offers a 
      safe, efficacious, and cost-effective treatment option for ID. It exhibits 
      comparable efficacy to FCM and IS but presents a better safety profile and 
      economic advantage. FDI fulfills the criteria of efficacy, safety, economy, 
      innovation, suitability, and accessibility, making it a promising choice for ID 
      management in China.
CI  - Copyright (c) 2023, Yun et al.
FAU - Yun, Lu
AU  - Yun L
AD  - School of International Pharmaceutical Business, China Pharmaceutical University, 
      Nanjing, CHN.
FAU - YuMei, Zhu
AU  - YuMei Z
AD  - School of International Pharmaceutical Business, China Pharmaceutical University, 
      Nanjing, CHN.
FAU - Bn, Vallish
AU  - Bn V
AD  - Department of Health Economics and Outcomes Research, Biostatistics, and 
      Medicine, MarksMan Healthcare Communications, Hyderabad, IND.
FAU - Tang, Qingu
AU  - Tang Q
AD  - School of International Pharmaceutical Business, China Pharmaceutical University, 
      Nanjing, CHN.
FAU - Feng, Chang
AU  - Feng C
AD  - School of International Pharmaceutical Business, China Pharmaceutical University, 
      Nanjing, CHN.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231113
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10716724
OTO - NOTNLM
OT  - cost-effectiveness
OT  - efficacy
OT  - ferric carboxymaltose
OT  - ferric derisomaltose
OT  - iron deficiency
OT  - iron sucrose
OT  - rapid health technology assessment
OT  - safety
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2023/12/14 06:42
MHDA- 2023/12/14 06:43
PMCR- 2023/11/13
CRDT- 2023/12/14 04:17
PHST- 2023/11/13 00:00 [accepted]
PHST- 2023/12/14 06:43 [medline]
PHST- 2023/12/14 06:42 [pubmed]
PHST- 2023/12/14 04:17 [entrez]
PHST- 2023/11/13 00:00 [pmc-release]
AID - 10.7759/cureus.48717 [doi]
PST - epublish
SO  - Cureus. 2023 Nov 13;15(11):e48717. doi: 10.7759/cureus.48717. eCollection 2023 
      Nov.